Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Back
Association details:
Biomarker:
CD133 overexpression
Cancer:
Hepatocellular Cancer
Drug:
sorafenib
(
Multi-tyrosine kinase inhibitor
,
pan-RAF inhibitor
)
Direction:
Resistant
Evidence:
Evidence Level:
Resistant: C3 – Early Trials
New
Source:
Gut Liver
Title:
Stem Cell Markers Predict the Response to Sorafenib in Patients with Hepatocellular Carcinoma
Excerpt:
Overexpression of the CSC markers CD133 and CD90 in HCC was associated with poorer response to sorafenib.
DOI:
10.5009/gnl18345
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login